PROM2 decreases cisplatin sensitivity in non-small cell lung cancer and is regulated by CTCF


  • Jiyang Tang The Third Affiliated Hospital of ZunYi Medical University (The First People's Hospital of ZunYi)
  • Dejun Shu
  • Zhimin Fang
  • Gaolan Yang


Background: Non-small cell lung cancer (NSCLC) is the major pathological type of lung cancer and accounts for the majority of lung cancer-related deaths worldwide. We investigate the molecular mechanism of prominin 2 (PROM2) involved in cisplatin resistance in NSCLC.

Methods: The GEOdatabase was analyzed to obtain differential genes to target PROM2. Immunohistochemistry and western blotting were used to detect protein expression levels. To examine the role of PROM2 in NSCLC, we overexpressed or knocked down PROM2 by plasmid or small interfering RNA. In functional experiments, CCK8 was used to detect cell viability. Cell migration and invasion and apoptosis were detected by transwell assay and flow cytometry, respectively. Mechanistically, the regulation of PROM2 by CTCF was detected by ChIP-PCR. In vivo experiments confirmed the role of PROM2 in NSCLC.

Results: GEO data analysis revealed that PROM2 was up-regulated in NSCLC, but its role in NSCLC remains unclear. Our clinical samples confirmed that the expression of PROM2 was markedly increased in NSCLC. Functionally, Overexpression of PROM2 promotes cell proliferation, migration and invasion, and cisplatin resistance. CTCF up-regulates PROM2 expression by binding to its promoter region. In vivo experiments confirmed that PROM2 knockdown could inhibit tumor growth and increase the sensitivity of tumor cells to cisplatin.

Conclusion: PROM2 up-regulation in NSCLC can attenuate the sensitivity of NSCLC cells to cisplatin and promote the proliferation, migration and invasion of tumor cells. PROM2 may provide a new idea for the treatment of NSCLC.




How to Cite

Tang, J., Dejun Shu, Zhimin Fang, & Gaolan Yang. (2023). PROM2 decreases cisplatin sensitivity in non-small cell lung cancer and is regulated by CTCF. Radiology and Oncology, 57(3), 325–336. Retrieved from



Experimental oncology